key: cord-1001333-12n938z2 authors: Chakraborty, Chiranjib; Sharma, Ashish Ranjan; Bhattacharya, Manojit; Lee, Sang-Soo title: Lessons Learned from Cutting-Edge Immunoinformatics on Next-Generation COVID-19 Vaccine Research date: 2021-07-10 journal: Int J Pept Res Ther DOI: 10.1007/s10989-021-10254-4 sha: 5482e334f21d44f3b948356cfd2255d589d1cdb6 doc_id: 1001333 cord_uid: 12n938z2 Presently, immunoinformatics and bioinformatics approaches are contributing actively to COVID-19 vaccine research. The first immunoinformatics-based vaccine construct against SARS-CoV-2 was published in February 2020. Following this, immunoinformatics and bioinformatics approaches have created a new direction in COVID-19 vaccine research. Several researchers have designed the next-generation COVID-19 vaccines using these approaches. Presently, immunoinformatics has accelerated immunology research immensely in the area of COVID-19. Hence, we have tried to depict the current scenario of immunoinformatics and bioinformatics in COVID-19 vaccine research. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s10989-021-10254-4. The COVID-19 vaccines have rolled out worldwide, and the vaccination program has started in different countries. More than 13 approved vaccine candidates are being used throughout the world for the mass vaccination program. Among them, Pfizer (BioNTech mRNA vaccine: BNT162b2) and ModernaTX mRNA vaccine (mRNA-1273) are the first approved vaccines, which have shown excellent efficacy (95% and 94.1%, respectively) (Chakraborty et al. 2021a, b) . These vaccines are capable of reducing COVID-19 infection. However, DNA-based (Ad5-nCoV) and peptide-based (EpiVacCorona) vaccines are also being used for vaccination (Table S1 ). Most of the vaccines are based on viral S (Spike) protein as the vital vaccine antigen. If we look back at the COVID-19 vaccine research scenario, the first vaccine research against SARS-CoV-2 was initiated using immunoinformatics. The first vaccine construct of the SARS-CoV-2 was reported in the Journal of Medical Virology on 28 February 2020 online (Bhattacharya et al. 2020a ). Chakraborty and his colleagues are the first group of researchers who have developed a next-generation epitope-based peptide vaccine construct, and the vaccine construct was generated through immunoinformatics. Moreover, Chakraborty and his colleagues analyzed this vaccine's stability, safety, and efficacy through immunoinformatics, showing that this next-generation vaccine candidate is safe and immunogenic (Bhattacharya et al. 2020b) . Likewise, some vaccine development companies have used immunoinformatic techniques to search for the most antigenic epitope for the vaccine candidate development. After the beginning of COVID-19 in December 2019 in China, WHO declared a health emergency on 30 January 2020. Since then, researchers have intensified the search for therapeutics against SARS-CoV-2 (Baden and Rubin 2020). Several clinical trials have been performed in this direction, where more than 100 countries have participated. A report shows that 3754 clinical trials had been completed for COVID-19. It has been noted that some of these clinical trial results had not been updated in trial repositories (Rodgers et al. 2021) . Quite a few therapeutics have given better results in clinical trials for severe COVID-19 patients Chiranjib Chakraborty and Ashish Ranjan Sharma contributed equally to this work. until today. Some therapeutic molecules have proven helpful for the treatment of COVID-19, which includes remdesivir (an antiviral molecule), baricitinib (an immunosuppressive molecule), dexamethasone (an immunosuppressive molecule), and some monoclonal antibodies (Collins 2021) . At first, most researchers tried to search for therapeutics by repurposing existing drugs. However, selected drugs have not provided accurate and successful outcomes. Therefore, the only way to stop the pandemic is to vaccinate the people to develop immunity against COVID-19 by using approved vaccines. Presently new SARS-CoV-2 variant (VOC; variants of concern and VOI: variants of interest) are a concern for the whole world. The vaccine candidate using alternative multi-epitopes for Wuhan strain and significant variant can be a solution . Collectively, it has been well accepted that the vaccine is the only effective option to stop this pandemic situation. Immunoinformatics and bioinformatics have a significant role in COVID-19 vaccine research, especially in antigenic epitopes selection and vaccine construct development ( Fig. 1) . Bioinformatics, immunoinformatics, vaccinogenomics, structural biology, and molecular dynamics simulations have contributed significantly to COVID-19 vaccine research. It was observed that several vaccine constructs were developed using immunoinformatics and bioinformatics. We performed PubMed search and found that approximately 24 vaccine constructs have been developed through immunoinformatics and bioinformatics to date (Table 1) . Simultaneously, several scientists identified T cell epitopes, B cell epitopes, and common T and B cell epitopes (Table 2 ) (Chakraborty et al. 2021c) . The selected epitopes have suggested that the identified common epitopes can be used for vaccine construct development. However, the researchers did not further analyze the identified epitopes to develop vaccine constructs, having several essential parameters like allergenicity and immunogenicity, utilizing immunoinformatics and bioinformatics. It was observed that only a few groups of scientists developed the vaccine construct against SARS-CoV-2 and performed docking with the Toll-like Receptor (TLR) group of molecules to understand the TLR based downstream regulation of the protective/adaptive immunity. Simultaneously, quite a few scientists have analyzed the complex stability with molecular dynamics simulation. Furthermore, we have found that a small number of scientist groups evaluated the vaccine construct's allergenicity Ranga et al. (2020) 14. Ashik A., et al., 2020 Bangladesh 3 epitopes Altered epitopes were predicted from the S-protein of SARS-CoV-2 Ashik et al. (2020) and immunogenicity. Even few researchers have performed normal mode analysis (NMA) analyses, in-silico cloning of vaccine candidates, and analyzed the physicochemical properties using immunoinformatics and bioinformatics. Analysis of the physicochemical properties is necessary to understand the solubility, molecular weight, theoretical isoelectric point (pI), estimated half-life, instability index, aliphatic index, and grand average of hydropathicity (GRAVY) of the vaccine candidate. All these steps are very crucial for evaluating a successful vaccine construct while utilizing bioinformatics and immunoinformatics. On 10 January 2020, the Chinese research group was the first to sequence the SARS-CoV-2 genome. Zhang and his colleagues sequenced the genome at Fudan University and made it publicly available in GenBank (Fan et al. 2020; Triggle et al. 2020) . After the availability of the genome sequence in GenBank, several researchers started to identify the antigenic epitopes using the sequence through immunoinformatics and bioinformatics. Immunoinformatics approaches for COVID-19 vaccine research were triggered because of two reasons. Firstly, this approach can design the vaccine rapidly (Fig. 2) . Secondly, there was an urgency for the COVID-19 vaccine throughout the globe. Most researchers targeted viral spike (S)-protein in their vaccine design analysis to identify the epitopes as it was found from the previous studies that S-protein has the maximum antigenic epitope regions (Dai and Gao 2020) . In addition, the previous studies have also shown that S glycoprotein in the other coronaviruses (SARS-CoV-1, MERS-CoV-2) has the highest antigenic epitopes. So, this knowledge of the prior research helped the researchers to develop the COVID-19 vaccine candidates quickly. Alternatively, several researchers also tried to identify epitopic areas from other structural proteins (M protein, E protein, N protein)/ proteome along with S-protein. We have performed a comprehensive, advanced search on PubMed with the keywords "immunoinformatics" and "COVID-19" and found that 88 articles have been published so far on this topic (Fig. 3) . Most of the article deals with the immunoinformatics-based vaccine development, the safety and efficacy analysis of vaccine construct, and different immunological component analyses related to SARS-CoV-2. The immunoinformatics approach has also been applied to find out different vaccine constructs for other coronaviruses (SARS-CoV-1, MERS-CoV-2). Few of them even have tried to develop a trivalent subunit vaccine construct for three emerging coronaviruses using immunoinformatics approaches. Several immunoinformatic databases have been developed to illustrate the immunogenicity and virulence of glycoproteins of coronaviruses and others. One such example of a database is DBCOVP which provides the information about conserved B cell, and T cell epitopes predicted from the protein (Sahoo et al. 2021) . Epitope-based COVID-19 vaccines are the next-generation COVID-19 vaccines, posing a highly antigenic part and an adjuvant. The antigenic component is also selected through the common epitopes (B and T cell) selection procedure. It can be more effective in generating adaptive immunity. Also, the vaccine can trigger innate immunity and stimulate the secretion of protective cytokines through interaction with TLRs. However, these vaccines have shown some limitations. One such limitation observed was blood clot formation after using the COVID-19 vaccine made by AstraZeneca (Wolf et al. 2021) . Other types of vaccines (live attenuated COVID-19 vaccine) also have some limitations. For example, live attenuated vaccines may suffer secondary mutation, which can revive virulence from the attenuated microorganism and lead to the occurrence of disease. Immunoinformatics is now at the forefront of the development of the next-generation COVID-19 vaccine. Recently, Ishack and Lipner have published a significant commentary that described the immense role of immunoinformatics and bioinformatics on COVID-19 vaccine development (Ishack and Lipner 2021) . However, there are several challenges ahead for immunoinformatics in vaccine research that need to address instantly. Firstly, advancement in the development of algorithms for immunoinformatics and bioinformatics. These algorithms will help to perform a more accurate and faster calculation without any computational errors. Secondly, some algorithms are available to illustrate the adaptive and innate immunity scenario after vaccination; however, more research data (in vitro and in vivo) is required to validate their claim. Thirdly, consideration of several factors associated with effective multi-epitope vaccine construct activity, such as the combination of epitopes and peptide linkers. One such example is that the stability of the vaccine candidate depends on the linker peptide. Fourthly, no epitope-based vaccine has thrived against some diseases until today (e.g., HIV, malaria). For these diseases, the causative organism possesses several antigenic proteins. In these cases, epitopes of these proteins are not adequately mapped, and the highly potent antigenic protein is difficult to identify. Therefore more extensive researches are required in this direction. However, soon, immunoinformatics will address all the challenges for COVID-19 vaccine research and help to design next-generation vaccines for all the infectious diseases and neglected diseases in coming times. The online version contains supplementary material available at https:// doi. org/ 10. 1007/ s10989-021-10254-4. A multiple peptides vaccine against COVID-19 designed from the nucleocapsid phosphoprotein (N) and Spike Glycoprotein (S) via the immunoinformatics approach Peptides-based vaccine against SARS-n CoV-2 antigenic fragmented synthetic epitopes recognized by T cell and β-cell initiation of specific antibodies to fight the infection An immunoinformatics study on the spike protein of SARS-CoV-2 revealing potential epitopes as vaccine candidates Covid-19-the search for effective therapy Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV Immunoinformatic design of a COVID-19 subunit vaccine using entire structural immunogenic epitopes of SARS-CoV-2 A SARS-CoV-2 vaccine candidate: insilico cloning and validation Development of epitope-based peptide vaccine against novel coronavirus 2019 (SARS-COV-2): immunoinformatics approach Immunoinformatics approach to understand molecular interaction between multi-epitopic regions of SARS-CoV-2 spike-protein with TLR4/MD-2 complex A next-generation vaccine candidate using alternative epitopes to protect against wuhan and all significant mutant variants of SARS-CoV-2: an immunoinformatics approach Asian-origin approved COVID-19 vaccines and current status of COVID-19 vaccination program in Asia: a critical analysis Immunoinformatics approach for the identification and characterization of T cell and B cell epitopes towards the peptidebased vaccine against SARS-CoV-2 From COVID-19 to cancer mRNA vaccines: moving from bench to clinic in the vaccine landscape Bioinformatics analysis of epitope-based vaccine design against the novel SARS-CoV-2 COVID-19 lessons for research Immunoinformatic identification of B cell and T cell epitopes in the SARS-CoV-2 proteome Viral targets for vaccines against COVID-19 Contriving multi-epitope subunit of vaccine for COVID-19: immunoinformatics approaches A new coronavirus associated with human respiratory disease in China Immunoinformatics prediction of overlapping CD8+ IFN-γ and IL-4 inducer CD4+ T-cell and linear B-cell epitopes based vaccines against COVID-19 (SARS-CoV-2) Development of a novel platform of virus-like particle (VLP)-based vaccine against COVID-19 by exposing epitopes: an immunoinformatics approach Bioinformatics and immunoinformatics to support COVID-19 vaccine development Scrutinizing the SARS-CoV-2 protein information for designing an effective vaccine encompassing both the T-cell and B-cell epitopes An Immunoinformatics study to predict epitopes in the envelope protein of SARS-CoV-2 Epitope based vaccine prediction for SARS-COV-2 by deploying immuno-informatics approach Design of a peptidebased subunit vaccine against novel coronavirus SARS-CoV-2 Design of novel multiepitope constructs-based peptide vaccine against the structural S, N and M proteins of human COVID-19 using immunoinformatics analysis Immunogenomics guided design of immunomodulatory multi-epitope subunit vaccine against the SARS-CoV-2 new variants, and its validation through in silico cloning and immune simulation Immunoinformatics and molecular modeling approach to design universal multi-epitope vaccine for SARS-CoV-2 Bioinformatic prediction of potential T cell epitopes for SARS-Cov-2 Exploring the SARS-CoV-2 structural proteins for multiepitope vaccine development: an in-silico approach Development of multi-epitope peptide-based vaccines against SARS-CoV-2 Epitopebased peptide vaccines predicted against novel coronavirus disease caused by SARS-CoV-2 Immunoinformatics study to search epitopes of spike glycoprotein from SARS-CoV-2 as potential vaccine Prediction and evolution of B cell epitopes of surface protein in SARS-CoV-2 Designing an efficient multi-epitope vaccine displaying interactions with diverse HLA molecules for an efficient humoral and cellular immune response to prevent COVID-19 infection Frenkel-Morgenstern M (2020) Immunoinformatics and structural analysis for identification of immunodominant epitopes in SARS-CoV-2 as potential vaccine targets Designing a conserved peptide-based subunit vaccine against SARS-CoV-2 using immunoinformatics approach Immunoinformatic analysis of SARS-CoV-2 nucleocapsid protein and identification of COVID-19 vaccine targets Computational design of SARS-CoV-2 spike glycoproteins to increase immunogenicity by T cell epitope engineering Vaccine design from the ensemble of surface glycoprotein epitopes of SARS-CoV-2: an immunoinformatics approach Immunoinformatics-guided design of an epitopebased vaccine against severe acute respiratory syndrome coronavirus 2 spike glycoprotein Immunogenic SARS-CoV-2 epitopes: in silico study towards better understanding of COVID-19 disease-paving the way for vaccine development Identification of SARS-CoV-2 CT L epitopes for development of a multivalent subunit vaccine for COVID-19 Missing clinical trial data: the evidence gap in primary data for potential COVID-19 drugs Designing a next generation multiepitope based peptide vaccine candidate against SARS-CoV-2 using computational approaches DBCOVP: a database of coronavirus virulent glycoproteins Designing a multi-epitope vaccine against SARS-CoV-2: an immunoinformatics approach Design of a multi-epitope vaccine against SARS-CoV-2 using immunoinformatics approach Immuno-informatics approach for B-cell and T-cell epitope based peptide vaccine design against novel COVID-19 virus Computationally validated SARS-CoV-2 CTL and HTL Multi-Patch vaccines, designed by reverse epitomics approach, show potential to cover large ethnically distributed human population worldwide Designing of a next generation multiepitope based vaccine (MEV) against SARS-COV-2: immunoinformatics and in silico approaches Immunoinformatic analysis of the SARS-CoV-2 envelope protein as a strategy to assess cross-protection against COVID-19 COVID-19: learning from lessons to guide treatment and prevention interventions Reverse vaccinology assisted designing of multiepitope-based subunit vaccine against SARS-CoV-2 Immunoinformatic analysis of T-and B-cell epitopes for SARS-CoV-2 vaccine design Immunoinformatics and molecular docking studies predicted potential multiepitope-based peptide vaccine and novel compounds against novel SARS-CoV-2 through Virtual screening Thrombocytopenia and intracranial venous sinus thrombosis after "COVID-19 vaccine AstraZeneca" exposure Design an efficient multi-epitope peptide vaccine candidate against SARS-CoV-2: an in silico analysis